The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability.
HRQoL
anxiety
carcinoid
depression
post-traumatic stress disorder
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
20 Sep 2021
20 Sep 2021
Historique:
revised:
06
08
2021
received:
16
07
2021
accepted:
05
09
2021
pubmed:
2
10
2021
medline:
2
10
2021
entrez:
1
10
2021
Statut:
aheadofprint
Résumé
The COVID-19 pandemic has added another layer of complexity to the fears of patients with neuroendocrine tumors (NETs). Little is known regarding the psychological impact of the COVID-19 outbreak on patients with gastroenteropancreatic or bronchopulmonary (BP) NETs. We longitudinally surveyed the mental symptoms and concerns of NET patients during the plateau phase of the first (W1) and second epidemic waves (W2) in Italy. Seven specific constructs (depression, anxiety, stress, health-related quality of life, NET-related quality of life, patient-physician relationship, psychological distress) were investigated using validated screening instruments, including DASS-21, EORTC QLQ-C30, EORTC QLQ GI.NET21, PDRQ9 and IES-R. We enrolled 197 patients (98 males) with a median age of 62 years. The majority of the patients had G1/G2 neoplasms. Some 38% of the patients were on active treatment. At W1, the prevalence of depression, anxiety and stress was 32%, 36% and 26% respectively. The frequency of depression and anxiety increased to 38% and 41% at W2, whereas no modifications were recorded in the frequency of stress. Poor educational status was associated with higher levels of anxiety at both W1 (odds ratio [OR] = 1.33 ± 0.22; p = .07) and W2 (OR = 1.45 ± 0.26; p = .03). Notably, post-traumatic stress symptoms were observed in the 58% of the patients, and both single marital status (OR = 0.16, 95% confidence interval [CI] = 0.06-0.48; p = .0009) and low levels of formal education (OR = 0.47, 95% CI = 0.23-0.99; p = .05) predicted their occurrence. No significant deteriorations of health-related quality of life domains were observed from W1 to W2. High patient care satisfaction was documented despite the changes in health systems resource allocation. NET patients have an increased risk of developing post-traumatic stress symptoms as result of the COVID-19 pandemic. Specific screening measures and psychological interventions should be implemented in NET clinics to prevent, recognize and treat mental distress in this vulnerable population.
Identifiants
pubmed: 34596289
doi: 10.1111/jne.13041
pmc: PMC8646700
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13041Subventions
Organisme : Associazione per la Ricerca Biomolecolare Onlus, Acquaviva, Italy
ID : 2020
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 23583
Informations de copyright
© 2021 British Society for Neuroendocrinology.
Références
J Nucl Med. 2011 Sep;52(9):1361-8
pubmed: 21795361
Behav Res Ther. 1995 Mar;33(3):335-43
pubmed: 7726811
World J Gastroenterol. 2018 Feb 14;24(6):671-679
pubmed: 29456406
Psychol Med. 2020 Jun 23;:1-10
pubmed: 32571438
J Endocrinol Invest. 2021 May;44(5):989-994
pubmed: 32803662
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cancer Med. 2021 Jun;10(12):3928-3937
pubmed: 33973411
Br J Cancer. 2013 Feb 5;108(2):301-10
pubmed: 23322194
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Clin Oncol. 2018 Sep 1;36(25):2578-2584
pubmed: 29878866
South Med J. 1973 Jul;66(7):787-90
pubmed: 4752229
Acta Oncol. 2001;40(7):825-31
pubmed: 11859981
Psychooncology. 2020 Sep;29(9):1377-1379
pubmed: 32779778
Acta Oncol. 2021 Jan;60(1):4-12
pubmed: 33031010
CA Cancer J Clin. 2018 Nov;68(6):471-487
pubmed: 30295930
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Transl Psychiatry. 2020 Jul 31;10(1):263
pubmed: 32737292
JAMA Oncol. 2021 Feb 1;7(2):279-284
pubmed: 33237294
Front Psychiatry. 2020 Dec 15;11:559701
pubmed: 33384620
Endocrine. 2021 Jan;71(1):14-19
pubmed: 33400173
J Gastrointest Cancer. 2021 Mar;52(1):369-373
pubmed: 33507439
Eur J Cancer Care (Engl). 2003 Mar;12(1):46-57
pubmed: 12641556
BMC Public Health. 2008 Oct 03;8:347
pubmed: 18831770
Eur J Cancer Care (Engl). 2002 Jun;11(2):91-9
pubmed: 12099944
J Neuroendocrinol. 2021 Sep 20;33(10):e13041
pubmed: 34596289
Support Care Cancer. 2021 Nov;29(11):6297-6304
pubmed: 33860361
Lancet Psychiatry. 2021 Feb;8(2):141-149
pubmed: 33308420
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Oncology. 2001;61(2):120-8
pubmed: 11528250
Front Oncol. 2020 Jul 10;10:1270
pubmed: 32754447
Front Psychol. 2020 Dec 23;11:616723
pubmed: 33424729
Ann Palliat Med. 2021 Apr;10(4):4601-4611
pubmed: 33966408
J Epidemiol Community Health. 2020 Sep;74(9):683-688
pubmed: 32503892
Psychosom Med. 2004 May-Jun;66(3):422-5
pubmed: 15184706
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
World J Gastroenterol. 2009 Oct 28;15(40):5067-73
pubmed: 19860000
Scand J Caring Sci. 2009 Mar;23(1):107-16
pubmed: 19250453
Gen Hosp Psychiatry. 2004 Mar-Apr;26(2):115-20
pubmed: 15038928
Support Care Cancer. 2018 Sep;26(9):3153-3161
pubmed: 29594486
Lancet Psychiatry. 2020 Oct;7(10):883-892
pubmed: 32707037